Hosted on MSN

Xenon projects top line X-TOLE2 data in early 2026 as enrollment surpasses target, expanding late-stage pipeline

Ian Mortimer, President and CEO, highlighted three critical priorities: completion of the Phase III X-TOLE2 study of azetukalner for focal onset seizures with top line data readout in early 2026; ...
Hosted on MSN

XENE stock rallies 50% on epilepsy trial data, but one analyst thinks rival Biohaven still has 'room to differentiate'

・Xenon plans to submit a new drug application for azetukalner to the U.S. Food and Drug Administration for the treatment of focal onset seizures in the third quarter of 2026. ・CEO Ian Mortimer said ...
Nasdaq

Insider Sale: PRESIDENT & CEO of $XENE Sells 16,217 Shares

IAN MORTIMER, the PRESIDENT & CEO of $XENE, sold 16,217 shares of the company on 01-23-2025 for an estimated $649,977. We received data on the trade from a recent SEC ...